Skip to main content
Reimbursement strategy

Market Access Strategy for Medical Devices in Europe

Strategic recommendations on the topic of market access pathways for medical devices and IVD tests

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Timelines for 2026 applications for DRG changes in Switzerland announced

In March 2026, the SwissDRG, the entity managing the DRG system in Switzerland, announced that it would be accepting applications for changes from June 1, 2026, until July 13, 2026. The application form became available for registered users on March 30, 2026.

Eligible applicants include the Swiss Medical Association (FMH), the Conference of the Cantonal Ministers of Public Health (GDK), the Medical Tariff Commission (MTK), health insurers, the Swiss Association of Hospitals (H+), and the hospitals. Other stakeholders can submit applications through an eligible organization.

The results of the DRG applications made in 2026 will be reflected in the 2028 version of the SwissDRG.

See the full details in German here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.